Glibornuride is a second-generation sulfonylurea antidiabetic agent used for the treatment of non-insulin-dependent diabetes mellitus (type 2 diabetes), particularly in adults over 40 years of age. It stimulates insulin secretion from pancreatic β-cells by binding to sulfonylurea receptors on the β-cell membrane. In addition to its hypoglycemic effect—approximately 20–40 times more potent than tolbutamide—it also reduces platelet adhesion and aggregation, decreases blood viscosity, increases prostacyclin levels, and lowers thromboxane A2, thereby improving microcirculation and helping prevent diabetic vascular complications. It may also lower serum triglyceride levels. Glibornuride remains an option for patients who have failed other sulfonylurea therapies.